BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 29849821)

  • 1. CRISPR/Cas9 Genome Editing of Epidermal Growth Factor Receptor Sufficiently Abolished Oncogenicity in Anaplastic Thyroid Cancer.
    Huang LC; Tam KW; Liu WN; Lin CY; Hsu KW; Hsieh WS; Chi WM; Lee AW; Yang JM; Lin CL; Lee CH
    Dis Markers; 2018; 2018():3835783. PubMed ID: 29849821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of lung cancer cell lines harboring EGFR T790M mutation by CRISPR/Cas9-mediated genome editing.
    Park MY; Jung MH; Eo EY; Kim S; Lee SH; Lee YJ; Park JS; Cho YJ; Chung JH; Kim CH; Yoon HI; Lee JH; Lee CT
    Oncotarget; 2017 May; 8(22):36331-36338. PubMed ID: 28422737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Super-Enhancer-Driven Oncogenic Transcription by CDK7 Inhibition in Anaplastic Thyroid Carcinoma.
    Cao X; Dang L; Zheng X; Lu Y; Lu Y; Ji R; Zhang T; Ruan X; Zhi J; Hou X; Yi X; Li MJ; Gu T; Gao M; Zhang L; Chen Y
    Thyroid; 2019 Jun; 29(6):809-823. PubMed ID: 30924726
    [No Abstract]   [Full Text] [Related]  

  • 4. Targeting the Highly Expressed microRNA miR-146b with CRISPR/Cas9n Gene Editing System in Thyroid Cancer.
    Santa-Inez DC; Fuziwara CS; Saito KC; Kimura ET
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo.
    Ferrari SM; Bocci G; Di Desidero T; Elia G; Ruffilli I; Ragusa F; Orlandi P; Paparo SR; Patrizio A; Piaggi S; La Motta C; Ulisse S; Baldini E; Materazzi G; Miccoli P; Antonelli A; Fallahi P
    Oncol Rep; 2018 May; 39(5):2225-2234. PubMed ID: 29517103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer.
    Zhang L; Zhang Y; Mehta A; Boufraqech M; Davis S; Wang J; Tian Z; Yu Z; Boxer MB; Kiefer JA; Copland JA; Smallridge RC; Li Z; Shen M; Kebebew E
    Oncotarget; 2015 Apr; 6(11):9073-85. PubMed ID: 25940539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thyroid Follicular Cell Loss of Differentiation Induced by MicroRNA miR-17-92 Cluster Is Attenuated by CRISPR/Cas9n Gene Silencing in Anaplastic Thyroid Cancer.
    Fuziwara CS; Saito KC; Kimura ET
    Thyroid; 2020 Jan; 30(1):81-94. PubMed ID: 31578932
    [No Abstract]   [Full Text] [Related]  

  • 8. HDAC1 and HDAC2 Double Knockout Triggers Cell Apoptosis in Advanced Thyroid Cancer.
    Lin CL; Tsai ML; Lin CY; Hsu KW; Hsieh WS; Chi WM; Huang LC; Lee CH
    Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30669676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Torin2 targets dysregulated pathways in anaplastic thyroid cancer and inhibits tumor growth and metastasis.
    Sadowski SM; Boufraqech M; Zhang L; Mehta A; Kapur P; Zhang Y; Li Z; Shen M; Kebebew E
    Oncotarget; 2015 Jul; 6(20):18038-49. PubMed ID: 25945839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carfilzomib potentiates CUDC-101-induced apoptosis in anaplastic thyroid cancer.
    Zhang L; Boufraqech M; Lake R; Kebebew E
    Oncotarget; 2016 Mar; 7(13):16517-28. PubMed ID: 26934320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CLM29 and CLM24, pyrazolopyrimidine derivatives, have antitumoral activity in vitro in anaplastic thyroid cancer, with or without BRAF mutation.
    Fallahi P; Ferrari SM; La Motta C; Materazzi G; Bocci G; Da Settimo F; Miccoli P; Antonelli A
    Endocrine; 2016 Jul; 53(1):136-44. PubMed ID: 26286966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting CDK12-mediated transcription regulation in anaplastic thyroid carcinoma.
    Geng M; Yang Y; Cao X; Dang L; Zhang T; Zhang L
    Biochem Biophys Res Commun; 2019 Dec; 520(3):544-550. PubMed ID: 31615655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell Cycle M-Phase Genes Are Highly Upregulated in Anaplastic Thyroid Carcinoma.
    Weinberger P; Ponny SR; Xu H; Bai S; Smallridge R; Copland J; Sharma A
    Thyroid; 2017 Feb; 27(2):236-252. PubMed ID: 27796151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aberrant lipid metabolism in anaplastic thyroid carcinoma reveals stearoyl CoA desaturase 1 as a novel therapeutic target.
    von Roemeling CA; Marlow LA; Pinkerton AB; Crist A; Miller J; Tun HW; Smallridge RC; Copland JA
    J Clin Endocrinol Metab; 2015 May; 100(5):E697-709. PubMed ID: 25675381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of BP-14, a novel cyclin-dependent kinase inhibitor, on anaplastic thyroid cancer cells.
    Allegri L; Baldan F; Mio C; Puppin C; Russo D; Kryštof V; Damante G
    Oncol Rep; 2016 Apr; 35(4):2413-8. PubMed ID: 26884249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anaplastic thyroid cancer: outcome and the mutation/expression profiles of potential targets.
    Wu H; Sun Y; Ye H; Yang S; Lee SL; de las Morenas A
    Pathol Oncol Res; 2015 Jul; 21(3):695-701. PubMed ID: 25588542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New targeted therapies for anaplastic thyroid cancer.
    Antonelli A; Fallahi P; Ulisse S; Ferrari SM; Minuto M; Saraceno G; Santini F; Mazzi V; D'Armiento M; Miccoli P
    Anticancer Agents Med Chem; 2012 Jan; 12(1):87-93. PubMed ID: 22043992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo.
    Antonelli A; Bocci G; La Motta C; Ferrari SM; Fallahi P; Ruffilli I; Di Domenicantonio A; Fioravanti A; Sartini S; Minuto M; Piaggi S; Corti A; Alì G; Di Desidero T; Berti P; Fontanini G; Danesi R; Da Settimo F; Miccoli P
    J Clin Endocrinol Metab; 2012 Apr; 97(4):E528-36. PubMed ID: 22278419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of selective inhibitors of Aurora kinases on anaplastic thyroid carcinoma cell lines.
    Baldini E; Tuccilli C; Prinzi N; Sorrenti S; Antonelli A; Gnessi L; Morrone S; Moretti C; Bononi M; Arlot-Bonnemains Y; D'Armiento M; Ulisse S
    Endocr Relat Cancer; 2014 Oct; 21(5):797-811. PubMed ID: 25074669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor receptor status in anaplastic thyroid carcinoma.
    Lee DH; Lee GK; Kong SY; Kook MC; Yang SK; Park SY; Park SH; Keam B; Park DJ; Cho BY; Kim SW; Chung KW; Lee ES; Kim SW
    J Clin Pathol; 2007 Aug; 60(8):881-4. PubMed ID: 17079354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.